the Association of Intestinal Microbial Metabolites and Cardiac Function in Acute Myocardial Infarction

Recruiting

• Conditions: Acute Myocardial Infarction
• Interventions: Diagnostic Test: diagnose

• Registration Number: NCT04955054
• Lead Sponsor: Peking University Third Hospital

Brief Summary

Recently, more and more studies have confirmed that intestinal flora is closely related to the occurrence and development of cardiovascular diseases.Bile acids (BAS), short chain fatty acids (SCFA) and trimethylamine oxide (TMAO), the main metabolites of intestinal flora, are the key mediators of the interaction between gut and host. We aim to explore the association of BAs and SCFA with cardiac function in patients with AMI.

Detailed Description

Cardiovascular disease is the leading cause of death in China, and acute myocardial infarction (AMI) is the main cause of death of cardiovascular disease. In recent years, clinical epidemiological studies have confirmed that intestinal flora is closely related to the occurrence and development of cardiovascular diseases such as diabetes, hyperlipidemia, hypertension, atherosclerosis, coronary heart disease, heart failure and so on. Bile acids (BAS), short chain fatty acids (SCFA) and trimethylamine oxide (TMAO), the main metabolites of intestinal flora, are the key mediators of the interaction between gut and host. It is suggested that intestinal flora and its metabolites participate in the pathophysiological process of cardiovascular disease through inflammation, oxidative stress and programmed death, and have the potential to be intervention targets. Basic and clinical studies have shown that TMAO is associated with the onset and poor prognosis of AMI by promoting the development of atherosclerosis and thrombosis, but there are few reports on the relationship between BAs or SCFA and AMI. We aim to explore the association of BAs and SCFA with cardiac function in patients with AMI.

Study Timeline

• Study Start: 2020-10-11
• Status Verified: 2021-06
• Study First Submitted: 2021-06-29
• Study First Submitted QC: 2021-06-29
• Last Update Submitted: 2021-06-29
• Study First Posted: 2021-07-08
• Last Update Posted: 2021-07-08
• Primary Completion: 2025-10-11
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

The patient, aged 18-85 years, had undergone coronary angiography and agreed to be enrolled and signed the informed consent.

AMI : according to ST segment elevation myocardial infarction diagnostic criteria.

UAP:

1. typical chest pain symptoms;
2. negative in markers of myocardial injury;
3. The stenosis of main coronary artery or its main branches is more than 50%

Control:

1. atypical chest pain symptoms
2. negative in markers of myocardial injury;
3. The stenosis of main coronary artery and its main branches is less than 50%

Read More

Exclusion Criteria

1. Acute infection or application of antibiotics in the past 3 months;
2. Chronic heart failure;
3. History of inflammatory or absorptive bowel disease and bowel resection;
4. Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 5 times of normal value);
5. Renal insufficiency (serum creatinine > 220μml/L or creatinine clearance rate < 30 ml/min);
6. Malignant tumor;
7. Autoimmune diseases;
8. Uninformed patients

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
AMI	diagnose	patients with acute myocardial infarction
UAP	diagnose	patients without unstable angina pectoris

Primary Outcome Measures

Name	Time	Method
the plasma levels of BAs and SCFA	one week	the plasma levels of bile acids and short chain fatty acid in fast

Trial Locations

Locations (1)

Peking University Third Hospital; 🇨🇳 Beijing, Beijing, China